Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Peritoneal Neoplasms 1Ovarian Neoplasms 1Metastatic Adenocarcinoma of the Pancreas 1Fallopian Tube Neoplasms 1Carcinoma 1

Interventions

Paclitaxel 3mirvetuximab soravtansine 2Bevacizumab 2rucaparib 1relacorilant 1pembrolizumab 1liposomal doxorubicin 1Topotecan 1Taxes 1Saline Solution 1Immunoglobulin G 1Glucose 1Docetaxel 1Disulfides 1Carboplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Fallopian Tube Neoplasms × 130-nm albumin-bound paclitaxel × Clear all
NCT05257408 2025-04-16

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Corcept Therapeutics

Phase 3 Active not recruiting
381 enrolled 1 FDA
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡